Sasanlimab
drug drugOn this page
Also known as PF-06801591RN-888
Summary
Sasanlimab (CHEMBL4298191) is a phase-3 clinical-stage antibody; indicated across 6 conditions including urothelial carcinoma and non-small cell lung carcinoma.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Antibody
- Indications: 6 conditions
- Clinical trials: 26
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4298191 |
| Name | Sasanlimab |
| Type | Antibody |
| Max phase | 3 |
Also known as: PF-06801591, RN-888, Sasanlimab, SASANLIMAB
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
4 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| urothelial carcinoma | 3 | MONDO:0040679 | EFO:0008528 |
| non-small cell lung carcinoma | 2 | MONDO:0005233 | EFO:0003060 |
| prostate adenocarcinoma | 1 | MONDO:0005082 | EFO:0000673 |
| neoplasm | 1 | MONDO:0005070 | EFO:0000616 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 26.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1 | 17 |
| PHASE2 | 4 |
| PHASE1/PHASE2 | 3 |
| PHASE3 | 1 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04165317 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer |
| NCT06218069 | PHASE2/PHASE3 | NOT_YET_RECRUITING | Immuno-pet IMaging ResPonses AdministeRed Immune CheckpoiNt InhibiTor |
| NCT04181788 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies |
| NCT05241340 | PHASE2 | ACTIVE_NOT_RECRUITING | Neoadjuvant Sasanlimab With Radiation as an in Situ Vaccine for Cisplatin-ineligible Muscle Invasive Bladder Cancer |
| NCT05665361 | PHASE1/PHASE2 | RECRUITING | Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) |
| NCT07123090 | PHASE2 | RECRUITING | A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma |
| NCT04585815 | PHASE1/PHASE2 | TERMINATED | Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study) |
| NCT05935748 | PHASE2 | TERMINATED | Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) |
| NCT06089265 | PHASE2 | COMPLETED | Ketohexokinase Inhibition in Hereditary Fructose Intolerance |
| NCT06447662 | PHASE1 | RECRUITING | A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. |
| NCT07206225 | PHASE1 | RECRUITING | A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer |
| NCT02573259 | PHASE1 | COMPLETED | A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors |
| NCT02616185 | PHASE1 | TERMINATED | A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR) |
| NCT04152018 | PHASE1 | TERMINATED | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. |
| NCT04254107 | PHASE1 | TERMINATED | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer |
| NCT04458259 | PHASE1 | TERMINATED | Study of PF-07265807 in Participants With Metastatic Solid Tumors. |
| NCT05061537 | PHASE1 | TERMINATED | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors |
| NCT05233436 | PHASE1 | TERMINATED | PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors |
| NCT05259397 | PHASE1 | WITHDRAWN | PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) |
| NCT06285097 | PHASE1 | TERMINATED | A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors |
| NCT06448364 | PHASE1 | TERMINATED | A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination |
| NCT06546553 | PHASE1 | TERMINATED | A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines. |
| NCT06580938 | PHASE1 | TERMINATED | A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer |
| NCT06704724 | PHASE1 | TERMINATED | A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. |
| NCT06870487 | PHASE1 | TERMINATED | A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers |
| NCT06974734 | PHASE1 | TERMINATED | A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- In clinical trials for: urothelial carcinoma, non-small cell lung carcinoma